Assessment of Spermicides by a Stripping Technique Against Human
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Quaternary Ammonium Compounds
FACT SHEET: Quaternary Ammonium Compounds Quaternary ammonium compounds, also known as “quats” or “QACs,” include a number of chemicals used as sanitizers and disinfectants, including benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, ammonium chloride, and stearalkonium chloride.[i] In general, quats cause toxic effects through all Mutagenicity routes of exposure including inhalation, Some quats have shown to be mutagenic and to ingestion, dermal application, and irrigation of damage animal DNA and DNA in human body cavities. Exposure to diluted solutions may lymphocytes at much lower levels than are result in mild irritation, while concentrated present in cleaning chemicals.[6] solutions are corrosive, causing burns to the skin and mucous Membranes. They can produce Antimicrobial Resistance systemic toxicity and can also cause allergic Genes have been discovered that mediate reactions.[2] resistance to quats. There has been an association of some of these genes with beta lactamase genes, Asthma and Allergies raising concern for a relationship between Of particular interest with regard to use as disinfectant resistance and antibiotic resistance.[7] disinfectants in the COVID-19 pandemic, quats increase the risk for asthma and allergic Reproductive Toxicity sensitization. Evidence from occupational Mice whose cages were cleaned with QACs had exposures shows increased risk of rhinitis and very low fertility rates. [8] Exposure to a common asthma -
Tonsillopharyngitis - Acute (1 of 10)
Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula -
FDA-2015-N-0101; and FDA-2016-N-0124
DE PARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 November 18, 2020 Docket Nos. FDA-1975-N-0012; FDA-2015-N-0101; and FDA-2016-N-0124 The American Cleaning Institute Attention: James Kim, PhD Vice President, Science and Regulatory Affairs 1401 H Street, N.W. Suite 700 Washington, D.C. 20005 Re: Benzalkonium Chloride, Benzethonium Chloride, Chloroxylenol, Ethanol, and Povidone-Iodine Dear Dr. Kim: This letter responds to The American Cleaning Institute’s (ACI’s) July 14, 2020 communication regarding the deferral from final rulemaking under the over-the-counter (OTC) Drug Review on benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine for use in nonprescription (often referred to as over-the-counter or OTC) consumer antiseptic wash, health care antiseptic, and consumer antiseptic rub drug products. In March 2016, FDA issued letters granting requests to defer three active ingredients— benzalkonium chloride, benzethonium chloride, and chloroxylenol—from inclusion in the final rulemaking for the December 2013 proposed rule for OTC consumer antiseptic washes (78 FR 76444). Similarly, in January 2017, FDA issued letters granting requests to defer six active ingredients—benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, povidone- iodine, and isopropyl alcohol—from inclusion in the final rulemaking for the May 2015 proposed rule for OTC health care antiseptics (80 FR 25166). In October 2017, FDA issued letters granting requests to defer three active -
NINDS Custom Collection II
ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC -
Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol
Journal of Functional Biomaterials Article Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol Michael Kemme * and Regina Heinzel-Wieland Department of Chemical Engineering and Biotechnology, Hochschule Darmstadt, University of Applied Sciences, Stephanstrasse 7, 64295 Darmstadt, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-6151-1638631 Received: 18 December 2017; Accepted: 9 January 2018; Published: 11 January 2018 Abstract: Profound screening and evaluation methods for biocide-releasing polymer films are crucial for predicting applicability and therapeutic outcome of these drug delivery systems. For this purpose, we developed an agar overlay assay embedding biopolymer composite films in a seeded microbial lawn. By combining this approach with model-dependent analysis for agar diffusion, antimicrobial potency of the entrapped drug can be calculated in terms of minimum inhibitory concentrations (MICs). Thus, the topical antiseptic 4-hexylresorcinol (4-HR) was incorporated into poly(lactic-co-glycolic acid) (PLGA) films at different loadings up to 3.7 mg/cm2 surface area through a solvent casting technique. The antimicrobial activity of 4-HR released from these composite films was assessed against a panel of Gram-negative and Gram–positive bacteria, yeasts and filamentous fungi by the proposed assay. All the microbial strains tested were susceptible to PLGA-4-HR films with MIC values down to 0.4% (w/w). The presented approach serves as a reliable method in screening and quantifying the antimicrobial activity of polymer composite films. Moreover, 4-HR-loaded PLGA films are a promising biomaterial that may find future application in the biomedical and packaging sector. -
A Screening-Based Approach to Circumvent Tumor Microenvironment
JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL. -
AP76: 4-Hexyl-Resorcinol CAS#: 136-77-6
the art and science of smart patch testingTM AP76: 4-hexyl-resorcinol CAS#: 136-77-6 Patient Information Your patch test result indicates that you have a contact allergy to 4-hexyl- resorcinol. This contact allergy may cause your skin to react when it is exposed to this substance although it may take several days for the symptoms to appear. Typical symptoms include redness, swelling, itching, and fluid-filled blisters. Where is 4-hexyl-resorcinol found? 4-hexyl-resorcinol has a long history of human pharmaceutical use as a topical skin and mucosal disinfectant for treatment of superficial wounds, and as a component of soaps, handwashes, and skin cleaners. 4-hexyl-resorcinol has been used in dilute solutions as antiseptic gargles or throat spray, and in lozenges. 4-hexyl-resorcinol is still marketed today as an ingredient of certain throat lozenges. How can you avoid contact with 4-hexyl-resorcinol? Avoid products that list any of the following names in the ingredients: 1,3-Benzenediol, 4-hexyl- Cystoids anthelmintic 1,3-Dihydroxy-4-hexylbenzene EINECS 205-257-4 1,3-Dihydroxy-4-n-hexylbenzene Gelovermin 4-(1-Hexyl)resorcinol Hexylresorcin [German] 4-06-00-06048 (Beilstein Handbook Ref) Hexylresorcinol 4-Hexyl-1,3-benzenediol Hexylresorcinolum 4-Hexyl-1,3-dihydroxybenzene Hexylresorzin 4-Hexylresorcine Hidesol 4-n-Hexylresorcinol HSDB 566 Adrover NCI-C55787 AI3-08055 NSC 1570 Antascarin Oxana Ascaricid p-Hexylresorcinol Ascarinol Prensol Ascaryl Resorcinol, 4-hexyl- BRN 2048312 S.T. 37 Caprokol ST 37 CCRIS 888 ST-37 Crystoids Worm-agen What are some products that may contain 4-hexyl-resorcinol? Cosmetics: Clearasil Adult Care Lotions and Skin Care: KOPNOL Mouthwash / Gargle Throat Lozenges: Sucrets Throat Spray *For additional information about products that might contain 4-hexyl-resorcinol, go to the Household Product Database online (http:/householdproducts.nlm.nih.gov) at the United States National Library of Medicine. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Alcohol Based Anti-Microbial Compositions with Cosmetic Appearance
Patentamt Europaisches ||| || 1 1| || || || 1 1| || || || || 1 1| (19) J European Patent Office Office europeen des brevets (11) EP 0 930 065 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51 ) |nt. CI.6: A61 K 7/48, A61 K 7/50, 21.07.1999 Bulletin 1999/29 ^61 |_ 2/Q0 (21) Application number: 99300394.6 (22) Date of filing : 20.01 .1 999 (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU • Jampani, Hanuman J. MC NL PT SE Grapevine, TX 76051 (US) Designated Extension States: • Newman, Jerry L. AL LT LV MK RO SI Arlington, TX 7601 6 (US) • Newman, Anthony W. (30) Priority: 20.01.1998 US 9491 Fort Worth, TX 761 1 1 (US) (71) Applicant: ETHICON INC. (74) Representative: Somerville New Jersey 08876 (US) Mercer, Christopher Paul et al Carpmaels & Ransford 43, Bloomsbury Square London WC1 A 2RA(GB) (54) Alcohol based anti-microbial compositions with cosmetic appearance (57) The present invention provides antimicrobial compositions containing high levels of alcohol, car- bomer polymers and antimicrobial agents. The present invention provides stable, high viscosity antimicrobial formulations possessing cosmetic characteristics. CM < LO CO o o CO o Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 EP 0 930 065 A2 Description [0001] This application is related to European patent application No. (claiming priority from USSN 09/009 489 - Attorney's ref: P020733EP) and European patent application No. (claiming 5 priority from USSN 09 -Attorney's ref: ) the disclosures of which are incorporated herein by reference. -
Wo 2010/127231 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 November 2010 (04.11.2010) WO 2010/127231 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every AOlN 33/12 (2006.01) A61K 31/14 (2006.01) kind of national protection available): AE, AG, AL, AM, AOlN 25/04 (2006.01) CIlD 3/26 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, AOlP 1/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US2010/033 148 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 30 April 2010 (30.04.2010) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/174,724 1 May 2009 (01 .05.2009) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): SIG¬ TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, NAL INVESTMENT AND MANAGEMENT CO. -
Sore Throat in Primary Care Project
Family Practice, 2015, Vol. 32, No. 3, 263–268 doi:10.1093/fampra/cmv015 Advance Access publication 25 March 2015 Epidemiology Sore throat in primary care project: a clinical score to diagnose viral sore throat Selcuk Mistika,*, Selma Gokahmetoglub, Elcin Balcic, and Fahri A Onukd Downloaded from https://academic.oup.com/fampra/article-abstract/32/3/263/695324 by guest on 31 July 2019 aDepartment of Family Medicine, bDepartment of Microbiology, cDepartment of Public Health, Erciyes University Medical Faculty, Kayseri, Turkey, and dBunyamin Somyurek Family Medicine Centre, Kayseri, Turkey. *Correspondence to Prof. S. Mistik, Department of Family Medicine, Erciyes University Medical Faculty, Kayseri 38039, Turkey; E-mail: [email protected] Abstract Objective. Viral agents cause the majority of sore throats. However, there is not currently a score to diagnose viral sore throat. The aims of this study were (i) to find the rate of bacterial and viral causes, (ii) to show the seasonal variations and (iii) to form a new scoring system to diagnose viral sore throat. Methods. A throat culture for group A beta haemolytic streptococci (GABHS) and a nasopharyngeal swab to detect 16 respiratory viruses were obtained from each patient. Over a period of 52 weeks, a total of 624 throat cultures and polymerase chain reaction analyses were performed. Logistic regression analysis was performed to find the clinical score. Results. Viral infection was found in 277 patients (44.3%), and GABHS infection was found in 116 patients (18.5%). An infectious cause was found in 356 patients (57.1%). Rhinovirus was the most commonly detected infectious agent overall (highest in November, 34.5%), and the highest GABHS rate was in November (32.7%). -
Quality Standards Body Care Ingredients Generated on May 5, 2014
Whole Foods Market - Quality Standards Body Care Ingredients Generated on May 5, 2014 This document is intended for internal company use to assist WFM buyers in making purchasing decisions. Products that do not meet the ingredient standards of this document may not be sold within the product category noted above at Whole Foods Market. We reserve the right to add or remove ingredient terms from the quality standards list or to change the acceptable/unacceptable status of any ingredient at any time. For more information about using these lists, please see http://rock.wholefoods.com/?p=1034. Please make sure that you are using a recently updated list; current quality standards lists are available from the Quality Standards website at http://connect/global/qshe/qualitystandards/food. If you have any questions about this list, please contact the quality standards team at [email protected]. Acceptable and unacceptable ingredients for regular (not premium) body care products. Item Name Type Status Qualifier Functions C12-15 alkyl lactate Body Care acceptable surfactant Glyceryl stearate citrate Body Care acceptable emollient 1,2 hexanediol Body Care acceptable solvent 2-carboxy-1methylpyridinium chloride Body Care acceptable skin conditioning agent 2-propanone Body Care acceptable In nail polish remover only solvent AA2G-Ascorbyl Glucoside Body Care acceptable skin lightener, antioxidant Acacia Decurrens/Jojoba/Sunflower Body Care acceptable texturizer Seed Wax/Polyglyceryl - 3 Esters acetamide MEA Body Care acceptable surfactant acetone